| Similar Articles |
|---|
 |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...   |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Bio-IT World
April 2006
Kevin Davies |
Microsoft Forges BioIT Alliance The software giant's fledgling alliance aims to bring together companies from a cross-section of the industry -- from biotech and Big Pharma to equipment manufacturers and software developers -- to collaborate on technology that will speed drug discovery. |
Bio-IT World
November 2006
Kevin Davies |
Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities. |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
Bio-IT World
November 2005
Kevin Davies |
A Win-Win Situation The inaugural Bridging Discovery and IT conference explored critical issues facing discovery, clinical, and IT teams struggling to communicate and collaborate in biopharma organizations. |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Bio-IT World
Dec 2006/Jan 2007
Allison Proffitt |
'An Unfortunate Storm': Tripos CEO Discusses Company Future Tripos announced that it has successfully sold its Discovery Informatics business to Vector Capital. Despite the company's difficulties, including a collapsed share price, president and CEO John McAllister is upbeat about the company's future. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Bio-IT World
May 19, 2004
John Russell |
Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
Bio-IT World
April 2006
John Russell |
Pfizer's Pursuit of Technology Can this $50-billion-plus, 115,000-employee behemoth succeed where other pharma giants have failed and successfully institutionalize the effort to find and develop critical new technology? Should it even try? |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Bio-IT World
March 17, 2004 |
Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006. |
Pharmaceutical Executive
May 1, 2007
Weiner & Hovde |
Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
August 2005 |
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Bio-IT World
September 2006
Kevin Davies |
Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping. |
Chemistry World
December 2006
Derek Lowe |
Opinion: In the Pipeline A look at the story behind the growing investment by western companies in medicinal chemistry research in China. |
Bio-IT World
March 8, 2005
Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. |
Bio-IT World
April 2007
Vicki Glaser |
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics. |
Bio-IT World
June 2005
Nancy J. Kelley |
Building Centers of Excellence in Translational Medicine New approaches to drug development that will be more effective in translating research to patient delivery will require the design and construction of new facilities that foster new ways of working among larger, multidisciplinary, teams of scientists and medical professionals in biology, chemistry, physics, mathematics, engineering, computer science, and, of course, information technology. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Bio-IT World
November 12, 2002
Debra Goldfarb |
Disruption --The Real Revolution What is the real promise of the genomic revolution? It is its power to unleash disruptive innovation -- technology that allows a new group of people with different skill sets to do things in a decentralized, less expensive way. |
Bio-IT World
October 2005
Scott Lundstrom |
Semantic Web: Safety and Innovation Semantic Web technologies will create opportunities for improvements in discovery, development, and safety. Pharmas and biotechs should move aggressively to pilot the use of semantic technologies in these areas. |
Pharmaceutical Executive
October 1, 2011
Atsushi Nagahisa |
Creating Customer Value: It's No Distant Dream The author speaks about how the pharmaceutical industry can fix today's greatest global policy challenge: leveraging hard science to address an enormous -- and growing -- burden of unmet medical need. |
Bio-IT World
December 15, 2003
Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Bio-IT World
June 17, 2004
Mark D. Uehling |
How to Spell Discovery Rapidly combining cosmos of chemical and biological data, Johnson & Johnson's multidisciplinary ABCD platform for drug discovery aims to give scientists access to more information -- and the ability to make better decisions |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Bio-IT World
June 17, 2004
Michael A. Greeley |
A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools. |
Bio-IT World
May 9, 2003
Vivien Marx |
The Sharper Image See it, capture it, mine it, find it. The budding field of image informatics is empowering biomedical research. |
Bio-IT World
March 2006
Mike May |
The Evolving Grid Computing System at J&J Johnson & Johnson is planning to double the size of its grid computing network and the number of applications that run on it by the end of this year, according to company executives. |
Pharmaceutical Executive
September 1, 2013
Jill Wechsler |
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies. |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
